The potential rescheduling of cannabis to Schedule III has been met with a mix of celebration and skepticism within the industry. While many view this as a significant step forward, I find myself in the camp of cautious observers. As someone who has closely followed and written about cannabis policy, I’ve long maintained that Schedule III is less about progress and more about creating a sweet spot for Big Pharma to dominate the cannabis market, leaving smaller players and consumers at a disadvantage.
Zac Efron is building an ambitious off-grid home in Australia that will incorporate hemp across…
Award-winning cannabis journalist and best-selling author David Downs highlights the hottest flowers blazing up the…
The bill, passed with bipartisan support, would allow terminally ill patients to use medical marijuana…
In the early ’90s, the SoCal trio of Bradley Nowell, Eric Wilson and Bud Gaugh…
New Jersey’s cannabis market is not in its baby teeth era anymore. The state has…
Before pre-rolls were everywhere and convenience became a selling point, the blunt already had a…